Eric Venker
Director, Chief Executive Officer; President & Immunovant CEO · 10 filings · Latest: Jul 27, 2026
Immunovant, Inc.
Roivant Sciences Ltd.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
ROIV | Eric Venker | President & Immunovant CEO | Jul 27, 2026 | Sale | $34.95 | 200,000 | $7.0M | 1,613,063 | |
ROIV | Eric Venker | President & Immunovant CEO | Jul 27, 2026 | Option Exercise | $3.85 | 200,000 | $770.0K | 1,813,063 | |
ROIV | Venker Eric | — | Jul 27, 2026 | Proposed Sale | $34.95 | 200,000 | $7.0M | — | |
IMVT | Eric Venker | Director, Chief Executive Officer | Jul 2, 2026 | Sale | $38.48 | 3,092 | $119.0K | 254,280 | |
IMVT | Eric Venker | Director, Chief Executive Officer | Jul 1, 2026 | Option Exercise | $14.46 | 92,188 | $1.3M | 344,001 | |
ROIV | Eric Venker | President & Immunovant CEO | Jun 24, 2026 | Sale | $33.16 | 200,000 | $6.6M | 1,613,063 | |
ROIV | Eric Venker | President & Immunovant CEO | Jun 24, 2026 | Option Exercise | $3.85 | 200,000 | $770.0K | 1,813,063 | |
ROIV | Venker Eric | — | Jun 24, 2026 | Proposed Sale | $33.16 | 200,000 | $6.6M | — | |
ROIV | Eric Venker | President & Immunovant CEO | May 22, 2026 | Sale | $30.27 | 200,000 | $6.1M | 1,613,063 | |
ROIV | Eric Venker | President & Immunovant CEO | May 22, 2026 | Option Exercise | $3.85 | 200,000 | $770.0K | 1,813,063 | |
ROIV | Venker Eric | — | May 22, 2026 | Proposed Sale | $30.27 | 200,000 | $6.1M | — | |
ROIV | Eric Venker | President & Immunovant CEO | Apr 20, 2026 | Sale | $29.59 | 200,000 | $5.9M | 1,647,546 | |
ROIV | Eric Venker | President & Immunovant CEO | Apr 20, 2026 | Option Exercise | $3.85 | 200,000 | $770.0K | 1,847,546 | |
ROIV | Venker Eric | — | Apr 20, 2026 | Proposed Sale | $29.59 | 200,000 | $5.9M | — | |
IMVT | Eric Venker | Director, Chief Executive Officer | Apr 2, 2026 | Sale | $24.10 | 14,229 | $342.9K | 19,561 | |
IMVT | Eric Venker | Director, Chief Executive Officer | Apr 1, 2026 | Option Exercise | $14.46 | 368,750 | $5.3M | 368,750 | |
ROIV | Eric Venker | President & Immunovant CEO | Mar 17, 2026 | Sale | $28.24 | 200,000 | $5.6M | 1,647,546 | |
ROIV | Eric Venker | President & Immunovant CEO | Mar 17, 2026 | Option Exercise | $3.85 | 200,000 | $770.0K | 1,847,546 | |
ROIV | Venker Eric | — | Mar 17, 2026 | Proposed Sale | $28.24 | 200,000 | $5.6M | — | |
ROIV | Eric Venker | President & Immunovant CEO | Feb 13, 2026 | Sale | $26.49 | 200,000 | $5.3M | 1,654,597 |
Page 1 of 3
Next →